Previous close | 5.50 |
Open | 5.70 |
Bid | 3.10 |
Ask | 6.90 |
Strike | 2.00 |
Expiry date | 2025-01-17 |
Day's range | 5.70 - 5.70 |
Contract range | N/A |
Volume | |
Open interest | 13 |
NEW YORK, June 02, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), Chief Executive Silviu Itescu provided a corporate update at the Bell Potter Emerging Leaders Conference. Dr. Itescu reiterated that the Company expects to file this quarter the Biologics License Application (BLA) resubmission with the United States Food and Drug Administration (FDA) for its lead product candidate Ryoncil®(remestemcel-L) in the treatment of steroid-refractory acute graft versus host disease, wi
Amidst a generally downward trend in the ASX200, with notable dips in sectors like materials and utilities, there are still segments showing resilience, such as industrials. In this context, identifying growth companies with high insider ownership can offer investors potential stability and commitment from those who know the companies best.
In the past week, the Australian market has experienced a slight decline of 1.0%, though it has shown a robust increase of 8.4% over the past year with earnings expected to grow by 14% annually. In this context, stocks with high insider ownership can be particularly compelling as they often indicate that those who know the company best are betting on its success.